Novo Nordisk stock closed at DKK270.4 after Q3 2026 numbers hit the tape, with traders reacting to the headline wobble in quarterly earnings per share and net profit. On a three month view the share price is still down 11.4%, so short term holders are treating every miss or mixed line as a trading event rather than a business update.

The more important story sits in the longer run profit engine. Trailing twelve month earnings of DKK113.2b and a P/E of 10.5x against higher industry multiples keep the focus on whether this profitability trend and valuation gap can coexist for long.

Love Novo Nordisk’s profit engine but unsure how long a 10.5x P/E and that valuation gap can last? Compare it with a curated list of profitable peers in our